Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection

被引:62
作者
Lee, S. R. [1 ]
Yearwood, G. D. [1 ]
Guillon, G. B. [1 ]
Kurtz, L. A. [1 ]
Fischl, M. [1 ]
Friel, T. [2 ]
Berne, C. A. [3 ]
Kardos, K. W. [1 ]
机构
[1] OraSure Technol Inc, Bethlehem, PA 18015 USA
[2] Lehigh Valley Hosp, Allentown, PA 18102 USA
[3] Biol Specialty Corp, Colmar, PA 18915 USA
关键词
Rapid; HCV; Diagnosis; VIRUS-INFECTION; VIRAL-HEPATITIS; UNITED-STATES; ENZYME-IMMUNOASSAY; BLOOD-DONORS; ANTI-HCV; POPULATION; PREVALENCE; DISEASE; RISK;
D O I
10.1016/j.jcv.2010.02.018
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Despite considerable evolution in the quality of laboratory-based testing for detection of HCV, the availability of rapid, point-of-care tests may increase diagnoses by increasing opportunities for testing outside of traditional laboratory settings. Objectives: We evaluated the performance of a new, rapid HCV test that can be used with venous blood, finger stick blood, serum, plasma, or oral fluid and compared it to FDA-approved laboratory methods. Study design: HCV positive subjects as well as subjects at low risk for HCV were tested with the rapid test using all 5 specimen types and results compared to FDA-approved laboratory methods. In addition, performance was assessed in commercially available seroconversion panels. Results: Sensitivity and specificity of the rapid test was equivalent to laboratory EIA and performance was comparable across all 5 specimen types. Conclusions: The OraQuick(R) HCV Rapid Antibody Test appears suitable as an aid in the diagnosis of HCV infection. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:15 / 17
页数:3
相关论文
共 22 条
[1]  
[Anonymous], 1999, 49 WHO
[2]   The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 [J].
Armstrong, Gregory L. ;
Wasley, Annemarie ;
Simard, Edgar P. ;
McQuillan, Geraldine M. ;
Kuhnert, Wendi L. ;
Alter, Miriam J. .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :705-714
[3]   IMPROVED DETECTION OF ANTI-HCV IN POSTTRANSFUSION HEPATITIS BY A 3RD-GENERATION ELISA [J].
BARRERA, JM ;
FRANCIS, B ;
ERCILLA, G ;
NELLES, M ;
ACHORD, D ;
DARNER, J ;
LEE, SR .
VOX SANGUINIS, 1995, 68 (01) :15-18
[4]   ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME [J].
CHOO, QL ;
KUO, G ;
WEINER, AJ ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :359-362
[5]   Projecting future complications of chronic hepatitis C in the United States [J].
Davis, GL ;
Albright, JE ;
Cook, SF ;
Rosenberg, DM .
LIVER TRANSPLANTATION, 2003, 9 (04) :331-338
[6]   Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population [J].
Dodd, RY ;
Notari, EP ;
Stramer, SL .
TRANSFUSION, 2002, 42 (08) :975-979
[7]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[8]  
GRAY JW, 2004, POINT CARE TESTING, P361
[9]  
JOHNSTONROBERTS K, 2007, AIDS PATIENT CARE ST, V21, P621
[10]   INCREASED DETECTION OF HEPATITIS C VIRUS (HCV)-INFECTED BLOOD-DONORS BY A MULTIPLE-ANTIGEN HCV ENZYME-IMMUNOASSAY [J].
KLEINMAN, S ;
ALTER, H ;
BUSCH, M ;
HOLLAND, P ;
TEGTMEIER, G ;
NELLES, M ;
LEE, S ;
PAGE, E ;
WILBER, J ;
POLITO, A .
TRANSFUSION, 1992, 32 (09) :805-813